NSP10-Mimicking Peptide Inhibitors With Low-Cytotoxicity SARS-CoV-2 Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for COVID-19, particularly those targeting SARS-CoV-2, face challenges due to emerging virus strains resistant to neutralizing antibodies and the need for effective treatments that minimize cytotoxicity and resistance development.
Innovation Solution
Development of peptide inhibitors, such as P3, which mimic the NSP10 sequence of SARS-CoV-2, specifically targeting the Methyltransferase complex (NSP10/NSP16) to inhibit viral replication, using a modified cysteine and HIV Tat peptide for membrane penetration, and formulated with pharmaceutically acceptable carriers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide P1 (amino acids 68-96 of NSP10) is used to target Methyltransferase complex, then viral replication is inhibited, but high cytotoxicity occurs (CC50 1 μg/mL)
Solution Approach 1:
The peptide sequence is segmented to identify and remove the toxic Zinc knuckle motif (amino acids 68-79) while retaining the functional C-terminal region (amino acids 89-96) that binds to NSP16. This segmentation allows separation of toxic and functional elements, resulting in peptide P3 that maintains antiviral activity without cytotoxicity.
Solution Approach 2:
The harmful Zinc knuckle motif is extracted and removed from the original NSP10 sequence. Only the essential C-terminal binding region (amino acids 89-96) is retained to form peptide P3, eliminating the source of cytotoxicity while preserving the antiviral mechanism.
2Reliability
If neutralizing antibodies are used to target SARS-CoV-2, then viral infection is blocked, but resistance develops in emerging virus strains
Solution Approach 1:
Instead of directly targeting the viral surface proteins with antibodies, the peptide acts as an intermediary by binding to the host's NSP16 protein. This host-factor targeting strategy prevents direct viral mutation resistance while still blocking viral replication through inhibition of the methyltransferase complex.
Solution Approach 2:
The peptide targets a conserved host-viral interaction interface (NSP10/NSP16/NSP14 complexes) that is essential for coronavirus replication. This approach provides broad-spectrum activity against multiple coronavirus strains and variants, reducing the likelihood of resistance development compared to strain-specific antibody approaches.
3Object-affected harmful factors
If peptide P2 (with Histidine to Arginine mutation) is used to reduce toxicity, then cytotoxicity is eliminated, but antiviral activity is lost
Solution Approach 1:
The peptide is designed with local quality differentiation: the N-terminal region is modified to eliminate toxicity (removing Zinc knuckle), while the C-terminal region is preserved to maintain binding function. This localized modification approach ensures that toxicity reduction does not compromise antiviral activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
P3 effectively inhibits SARS-CoV-2 replication with low cytotoxicity and high specificity, reducing the likelihood of resistance and providing broad-spectrum efficacy against emerging strains.
Implementation Method 1
P3 comprises a peptide sequence from the HIV Tat to allow penetration of cell membrane
Data Source
AI summary
Synthetic peptides mimicking the nsp10 sequence in the region interacting with nsp16 capable of penetrating cell membranes and inhibiting SARS-CoV-2 replication for the treatment of moderate to severe COVID-19. The invention relates to peptides inhibiting SARS-CoV-2 replication, likely through inhibition of Methyltransferase complexes (NSP10/NSP16 and NSP10/NSP14). The peptide of the present invention, P3, contains sequences corresponding to amino acids 89-96 of the non-structural protein 10 (NSP10) of SARS-CoV-2, with the only Cysteine modified to a Methionine. This peptide was made based on two previous designs P1 and P2, which constituted the amino acids 68-96 of the NSP10 protein of SARS-CoV-2.